BACKGROUND: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis, which, if left untreated, can lead to permanent sight loss. We compared ultrasound as an alternative diagnostic test with temporal artery biopsy, which may be negative in 9-61% of true cases. OBJECTIVE: To compare the clinical effectiveness and cost-effectiveness of ultrasound with biopsy in diagnosing patients with suspected GCA. DESIGN: Prospective multicentre cohort study. SETTING: Secondary care. PARTICIPANTS: A total of 381 patients referred with newly suspected GCA. MAIN OUTCOME MEASURES: Sensitivity, specificity and cost-effectiveness of ultrasound compared with biopsy or ultrasound combined with biopsy for diagnosing GCA and interobser...
Objective: To evaluate the utility of ultrasound in aiding the diagnosis of giant cell arteritis (GC...
Early recognition of giant cell arteritis (GCA) is crucial to avoid the development of ischemic vasc...
Objective: To test the reliability of Outcome Measures in Rheumatology Clinical Trials (OMERACT) con...
Background: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis, w...
Background: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculiti...
ObjectiveTo evaluate the utility of ultrasound in aiding the diagnosis of giant cell arteritis (GCA)...
Objective. The aim of this study was to assess the usefulness of colour duplex sonography (CDS)-guid...
Objective: Giant cell arteritis (GCA) is a treatable, but potentially sight- and life-threatening fo...
Objective The main study objective was to determine how giant cell arteritis (GCA) is diagnosed in o...
Background: Giant cell arteritis (GCA) requires rapid diagnosis and treatment to prevent severe comp...
International audienceDespite major recent advances in the therapeutic management of Giant cell arte...
Background: Giant cell arteritis (GCA) has the potential to cause irreversible blindness and stroke ...
Background: Giant cell arteritis (GCA) is a vasculitis, varies in extent, severity and outcomes, hen...
Purpose: To assess the use of temporal artery biopsy (TAB) in diagnosing giant cell arteritis (GCA) ...
Background: Giant cell arteritis (GCA) is the commonest of the vasculitides and should form part of...
Objective: To evaluate the utility of ultrasound in aiding the diagnosis of giant cell arteritis (GC...
Early recognition of giant cell arteritis (GCA) is crucial to avoid the development of ischemic vasc...
Objective: To test the reliability of Outcome Measures in Rheumatology Clinical Trials (OMERACT) con...
Background: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis, w...
Background: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculiti...
ObjectiveTo evaluate the utility of ultrasound in aiding the diagnosis of giant cell arteritis (GCA)...
Objective. The aim of this study was to assess the usefulness of colour duplex sonography (CDS)-guid...
Objective: Giant cell arteritis (GCA) is a treatable, but potentially sight- and life-threatening fo...
Objective The main study objective was to determine how giant cell arteritis (GCA) is diagnosed in o...
Background: Giant cell arteritis (GCA) requires rapid diagnosis and treatment to prevent severe comp...
International audienceDespite major recent advances in the therapeutic management of Giant cell arte...
Background: Giant cell arteritis (GCA) has the potential to cause irreversible blindness and stroke ...
Background: Giant cell arteritis (GCA) is a vasculitis, varies in extent, severity and outcomes, hen...
Purpose: To assess the use of temporal artery biopsy (TAB) in diagnosing giant cell arteritis (GCA) ...
Background: Giant cell arteritis (GCA) is the commonest of the vasculitides and should form part of...
Objective: To evaluate the utility of ultrasound in aiding the diagnosis of giant cell arteritis (GC...
Early recognition of giant cell arteritis (GCA) is crucial to avoid the development of ischemic vasc...
Objective: To test the reliability of Outcome Measures in Rheumatology Clinical Trials (OMERACT) con...